Number of reps down 10% since 2007, says study

Share this article:
Job security for pharma sales reps is looking bleak, going by the results of a ZS Associates study. The survey found that the number of US reps has plummeted 10% since 2007 to 92,000, and the management consultancy projects a further decline, to 75,000 by 2012.

The data, first reported in the AMA's American Medical News, reflects industry efforts to cut costs as more doctors close their doors to drug reps.

According to TNS Healthcare, for every 100 reps who visit a physician's office, only 37 leave their company's product with the doc, while only 20 actually have a face-to-face encounter with the doctor. PriceWaterhouseCoopers reports that profit per drug rep visit dropped 23% from 2004 to 2005.

SK&A Information Services said about a quarter of physicians work in practices that prohibit visits with drug reps. Of those physicians who do see reps, 40% will meet with reps only with scheduled appointments.

Changes of recent years, including increasing time constraints on physicians, the curtailing of gifts to physicians by reps and emerging online communication channels, have contributed to the decline in face-to-face interaction.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...